XOMA - XOMA Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.44
+0.37 (+2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.07
Open16.13
Bid15.19 x 1300
Ask17.07 x 800
Day's Range16.13 - 16.53
52 Week Range15.35 - 37.25
Volume40,284
Avg. Volume103,823
Market Cap137.885M
Beta4.06
PE Ratio (TTM)8.73
EPS (TTM)1.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.00
Trade prices are not sourced from all markets
  • GlobeNewswire24 days ago

    XOMA to Present at the H. C. Wainwright 20th Annual Global Investment Conference

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, announced today its Chief Executive Officer, Jim Neal, will present at the H. C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018, at 11:40-12:05PM ET in New York, New York. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswirelast month

    XOMA to Present at the 2018 Wedbush PacGrow Healthcare Conference and the 2018 Southern California Investor Conference

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
    Zackslast month

    Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Xoma: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    XOMA Reports Second Quarter 2018 Financial Results

    EMERYVILLE, Calif., Aug. 07, 2018-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its second quarter 2018 financial results.. “We continue ...

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Alleghany, Enable Midstream Partners, LP, XOMA, MCBC, Unifi, and Tyler Technologies — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alleghany ...

  • GlobeNewswire3 months ago

    XOMA Added to the Russell 2000® and Russell 3000® Indexes

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 22, 2018. “We believe XOMA’s addition to these Russell indexes will enhance our visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer at XOMA. The Russell 3000® Index is a market capitalization-weighted equity index that tracks the performance of the largest 3,000 U.S. stocks.

  • Associated Press4 months ago

    Xoma: 1Q Earnings Snapshot

    The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Associated Press6 months ago

    Xoma reports 4Q loss

    The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...

  • AbbVie Presents New Data on Upadacitinib for Crohn's Disease
    Zacks7 months ago

    AbbVie Presents New Data on Upadacitinib for Crohn's Disease

    AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

  • FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
    Zacks7 months ago

    FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

    FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

  • AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
    Zacks7 months ago

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

  • Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
    Zacks7 months ago

    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

  • Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
    Zacks7 months ago

    Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

    Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

  • Pfizer Files for Xtandi in Early Stage Prostate Cancer
    Zacks7 months ago

    Pfizer Files for Xtandi in Early Stage Prostate Cancer

    Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

  • Puma, CANbridge Team Up to Commercialize Nerlynx in China
    Zacks8 months ago

    Puma, CANbridge Team Up to Commercialize Nerlynx in China

    Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

  • Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
    Zacks8 months ago

    Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

    Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.